141 related articles for article (PubMed ID: 11697540)
1. Pharmacokinetic behaviour of cisplatin in peritoneal fluid after intraperitoneal administration of cisplatin-loaded microspheres.
Tamura T; Imai J; Matsukawa Y; Horikiri Y; Suzuki T; Yoshino H; Ike O
J Pharm Pharmacol; 2001 Oct; 53(10):1331-9. PubMed ID: 11697540
[TBL] [Abstract][Full Text] [Related]
2. Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres.
Tamura T; Imai J; Matsumoto A; Tanimoto M; Suzuki A; Horikiri Y; Suzuki T; Yoshino H; Ike O
Eur J Pharm Biopharm; 2002 Jul; 54(1):1-7. PubMed ID: 12084496
[TBL] [Abstract][Full Text] [Related]
3. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.
Los G; Mutsaers PH; Ruevekamp M; McVie JG
Cancer Lett; 1990 May; 51(2):109-17. PubMed ID: 2344588
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
5. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
[TBL] [Abstract][Full Text] [Related]
6. Improvement of intraperitoneal chemotherapy for rat ovarian cancer using cisplatin-containing microspheres.
Kumagai S; Sugiyama T; Nishida T; Ushijima K; Yakushiji M
Jpn J Cancer Res; 1996 Apr; 87(4):412-7. PubMed ID: 8641974
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice.
Tamura T; Fujita F; Tanimoto M; Koike M; Suzuki A; Fujita M; Horikiri Y; Sakamoto Y; Suzuki T; Yoshino H
J Control Release; 2002 Apr; 80(1-3):295-307. PubMed ID: 11943406
[TBL] [Abstract][Full Text] [Related]
8. A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin.
Gunji S; Obama K; Matsui M; Tabata Y; Sakai Y
Surgery; 2013 Nov; 154(5):991-9. PubMed ID: 24008088
[TBL] [Abstract][Full Text] [Related]
9. Relation between dissolution profiles and toxicity of cisplatin-loaded microspheres.
Tamura T; Imai J; Tanimoto M; Matsumoto A; Suzuki A; Horikiri Y; Suzuki T; Yoshino H
Eur J Pharm Biopharm; 2002 Mar; 53(2):241-7. PubMed ID: 11880009
[TBL] [Abstract][Full Text] [Related]
10. An experimental study of regional chemotherapy using CDDP-loaded microspheres for esophageal cancer.
Nakamura Y; Hamabe Y; Ikuta H; Hyon SH; Kuroda Y
Surg Today; 2002; 32(4):335-42. PubMed ID: 12027199
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice.
Araújo JG; Mota Ld; Leite EA; Maroni Lde C; Wainstein AJ; Coelho LG; Savassi-Rocha PR; Pereira MT; de Carvalho AT; Cardoso VN; De Oliveira MC
Exp Biol Med (Maywood); 2011 Jul; 236(7):808-15. PubMed ID: 21685237
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic effects of cisplatin microspheres on peritoneal carcinomatosis in rodents.
Hagiwara A; Takahashi T; Kojima O; Yamaguchi T; Sasabe T; Lee M; Sakakura C; Shoubayashi S; Ikada Y; Hyon SH
Cancer; 1993 Feb; 71(3):844-50. PubMed ID: 8431867
[TBL] [Abstract][Full Text] [Related]
13. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs.
Yin JX; Wei Z; Xu JJ; Sun ZQ
Cancer Chemother Pharmacol; 2015 Sep; 76(3):525-36. PubMed ID: 26183605
[TBL] [Abstract][Full Text] [Related]
15. Experimental study on paratumoral injection of cisplatin-loaded microspheres for gastric cancer.
Narita K; Ikuta H; Hamabe Y; Kuroda Y
Kobe J Med Sci; 1999 Oct; 45(5):229-43. PubMed ID: 10853189
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal chemotherapy for peritoneal metastases using sustained release formula of cisplatin-incorporated gelatin hydrogel granules.
Yamashita K; Tsunoda S; Gunji S; Murakami T; Suzuki T; Tabata Y; Sakai Y
Surg Today; 2019 Sep; 49(9):785-794. PubMed ID: 30847629
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials with intraperitoneal cisplatin microspheres for malignant ascites--a pilot study.
Hagiwara A; Takahashi T; Sawai K; Sakakura C; Tsujimoto H; Osaki K; Sakakibara T; Ohyama T; Ohgaki M; Muranishi S
Anticancer Drug Des; 1993 Dec; 8(6):463-70. PubMed ID: 8286013
[TBL] [Abstract][Full Text] [Related]
18. [Studies on preparation and characteristics of cisplatin chitosan microspheres].
Wang YM; Shi TS; Pu YL; Zhu JG; Zhao YL
Yao Xue Xue Bao; 1996; 31(4):300-5. PubMed ID: 9208650
[TBL] [Abstract][Full Text] [Related]
19. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic analysis of intra-peritoneal administration of cisplatin].
Terashima M; Ikeda K; Takagane A; Sasaki N; Abe K; Araya M; Nishizuka S; Yonezawa H; Irinoda T; Nakaya T; Oyama K; Saito K
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1859-62. PubMed ID: 9382551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
